Status:

WITHDRAWN

Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)

Lead Sponsor:

Northwestern University

Collaborating Sponsors:

National Heart, Lung, and Blood Institute (NHLBI)

American Society for Transplantation

Conditions:

High Blood Pressure

Liver Transplant

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Liver transplantation is a high risk, high-cost intervention that extends life in over 8,000 patients in the US each year. Of those that receive transplants, 1 in 3 will have a complication related to...

Detailed Description

The study will involve a randomized crossover trial of two medications: amlodipine besylate 10mg and chlorthalidone 25mg daily by mouth. Amlodipine was selected as the dihydropyridine calcium channel ...

Eligibility Criteria

Inclusion

  • Liver transplant alone recipient
  • At least 90 days from transplant
  • Average daytime systolic blood pressure (SBP)\>140mmHG with 24h ambulatory blood pressure monitoring. Patients will be enrolled in 24h ambulatory blood pressure monitoring (ABPM) if they have hypertension (HTN) defined by diagnostic codes, treatment with antihypertensive medications for ≥ 2 months, and a history of office blood pressure readings ≥140/90 mmHg at two separate office visits.
  • Stable antihypertensive medical therapy (e.g., no change in current antihypertensive medications within 30d of screening)
  • No acute cellular rejection within 30d of screening

Exclusion

  • Contraindication to withholding calcium channel blockers (CCB) or beta-blocker (e.g., atrial fibrillation/flutter)
  • Treatment with other diuretics that cannot be held
  • Acute coronary syndrome or revascularization within 60d
  • Serum potassium \< 3.5 mEq/L
  • Serum sodium \< 135 mg/dL
  • Allergy to sulfa drugs
  • Estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73 m2 or on dialysis
  • Pregnant women

Key Trial Info

Start Date :

July 12 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 4 2023

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT05275907

Start Date

July 12 2022

End Date

October 4 2023

Last Update

October 13 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Northwestern University

Chicago, Illinois, United States, 60611

Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN) | DecenTrialz